TD Cowen Maintains Hold on Beta Bionics, Raises Price Target to $21
Benzinga Newsdesk 4 days ago
Analyst RatingsNewsPrice Target
TD Cowen analyst Mathew Blackman maintains Beta Bionics (NASDAQ:BBNX) with a Hold and raises the price target from $18 to $21.
TD Cowen analyst Mathew Blackman maintains Beta Bionics (NASDAQ:BBNX) with a Hold and raises the price target from $18 to $21.